Supernus Pharmaceuticals, Inc. (SUPN)
SUPN Stock Price Chart
Explore Supernus Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SUPN price movements and trends.
SUPN Company Profile
Discover essential business fundamentals and corporate details for Supernus Pharmaceuticals, Inc. (SUPN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1 May 2012
Employees
674.00
Website
https://www.supernus.comCEO
Jack A. Khattar
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
SUPN Financial Timeline
Browse a chronological timeline of Supernus Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.52, while revenue estimate is $175.00M.
Earnings released on 5 Aug 2025
EPS came in at $0.91 surpassing the estimated $0.47 by +93.62%, while revenue for the quarter reached $165.45M , missing expectations by -1.65%.
Earnings released on 6 May 2025
EPS came in at $0.42 surpassing the estimated $0.38 by +10.53%, while revenue for the quarter reached $149.82M , beating expectations by +1.28%.
Earnings released on 25 Feb 2025
EPS came in at $0.75 surpassing the estimated $0.46 by +63.04%, while revenue for the quarter reached $174.16M , beating expectations by +12.18%.
Earnings released on 4 Nov 2024
EPS came in at $1.06 surpassing the estimated $0.39 by +171.79%, while revenue for the quarter reached $175.69M , beating expectations by +13.70%.
Earnings released on 6 Aug 2024
EPS came in at $0.36 surpassing the estimated $0.31 by +16.13%, while revenue for the quarter reached $168.33M , beating expectations by +13.08%.
Earnings released on 8 May 2024
EPS came in at $0.26 falling short of the estimated $0.38 by -31.58%, while revenue for the quarter reached $143.64M , missing expectations by -1.50%.
Earnings released on 27 Feb 2024
EPS came in at $0.02 falling short of the estimated $0.41 by -95.12%, while revenue for the quarter reached $164.31M , beating expectations by +5.99%.
Earnings released on 8 Nov 2023
EPS came in at -$0.29 falling short of the estimated $0.13 by -323.08%, while revenue for the quarter reached $153.88M , missing expectations by -0.90%.
Earnings released on 8 Aug 2023
EPS came in at -$0.02 falling short of the estimated $0.23 by -108.70%, while revenue for the quarter reached $135.56M , missing expectations by -5.64%.
Earnings released on 9 May 2023
EPS came in at $0.29 surpassing the estimated $0.17 by +70.59%, while revenue for the quarter reached $153.76M , beating expectations by +10.61%.
Earnings released on 28 Feb 2023
EPS came in at $0.43 falling short of the estimated $0.68 by -36.76%, while revenue for the quarter reached $167.33M , missing expectations by -7.21%.
Earnings released on 8 Nov 2022
EPS came in at $0.03 falling short of the estimated $0.36 by -91.67%, while revenue for the quarter reached $177.35M , beating expectations by +2.83%.
Earnings released on 4 Aug 2022
EPS came in at $0.14 falling short of the estimated $0.29 by -51.72%, while revenue for the quarter reached $170.05M , beating expectations by +3.61%.
Earnings released on 13 Apr 2022
EPS came in at $0.04 falling short of the estimated $0.24 by -83.33%, while revenue for the quarter reached $152.51M , missing expectations by -0.91%.
Earnings released on 28 Feb 2022
EPS came in at $0.04 falling short of the estimated $0.24 by -81.34%, while revenue for the quarter reached $159.05M , beating expectations by +7.19%.
Earnings released on 3 Nov 2021
EPS came in at $0.40 surpassing the estimated $0.23 by +73.91%, while revenue for the quarter reached $148.46M , beating expectations by +25.70%.
Earnings released on 4 Aug 2021
EPS came in at $0.43 surpassing the estimated $0.20 by +115.00%, while revenue for the quarter reached $141.33M , beating expectations by +4.79%.
Earnings released on 5 May 2021
EPS came in at $0.11 falling short of the estimated $0.24 by -54.17%, while revenue for the quarter reached $130.93M , beating expectations by +1.17%.
Earnings released on 25 Feb 2021
EPS came in at $0.57 surpassing the estimated $0.52 by +9.62%, while revenue for the quarter reached $143.56M , missing expectations by -1.80%.
Earnings released on 3 Nov 2020
EPS came in at $0.74 surpassing the estimated $0.30 by +146.67%, while revenue for the quarter reached $155.14M , beating expectations by +536.09%.
SUPN Stock Performance
Access detailed SUPN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.